For production of monoclonal antibody (mAb) against human epidermal growth factor receptor (EGFR), first, five female Balb/c mice 6 to 8 weeks old were immunized against A431 tumoral cells that express more EGFR on its membrane in four periods and the most immune mouse was selected for fusion. The fusion of mouse's spleen immune cells with SP2/0 cells (myeloma cells) were fulfilled in presence of Poly Ethylene Glycol (PEG). Supernatant of hybridoma cells were screened for detection of antibody by ELISA. The suitable clones were selected for limiting dilution (L.D). Large scale of monoclonal antibodies was produced in vitro and ascetic fluid. In this investigation, 280 clones were obtained, 27 of which displayed absorbance more than 1. Of these, 3 clones represented absorbance about 1.7 and selected for limiting dilution. The yield of limiting dilution was 8 monoclones with absorbance about 2. These results indicate that such monoclonal antibodies against EGFR can be used in diagnosis and treatment of tumors with membranous EGFR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/HAB-2009-0195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoding the Molecular Basis of the Specificity of an Anti-sTn Antibody.
JACS Au
January 2025
UCIBIO-Applied Molecular Biosciences Unit, Department of Chemistry, NOVA School of Science and Technology, NOVA University Lisbon, 2829-516 Caparica, Portugal.
The mucin -glycan sialyl Tn antigen (sTn, Neu5Acα2-6GalNAcα1--Ser/Thr) is an antigen associated with different types of cancers, often linked with a higher risk of metastasis and poor prognosis. Despite efforts to develop anti-sTn antibodies with high specificity for diagnostics and immunotherapy, challenges in eliciting high-affinity antibodies for glycan structures have limited their effectiveness, leading to low titers and short protection durations. Experimental structural insights into anti-sTn antibody specificity are lacking, hindering their optimization for cancer cell recognition.
View Article and Find Full Text PDFSafety Evaluation of the Novel Cocktail of Monoclonal Antibodies for Postexposure Prophylaxis in Category III Animal Exposures.
J Glob Infect Dis
October 2024
Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India.
Introduction: Rabies monoclonal antibody (mAb) is a life-saving immune-biological for postexposure prophylaxis (PEP) in all Category III animal exposures. A novel cocktail of mAbs derived using recombinant DNA technology is presently available for usage. The WHO recommends monitoring the clinical use and outcomes of mAb products.
View Article and Find Full Text PDFComparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis.
BMC Pulm Med
January 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Introduction: Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined.
Methods: We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.go and randomised controlled trials (RCTs) from major international conferences for literature related to neoadjuvant immunotherapy combinations published as first-line treatment options for non-small cell lung cancer from the start of the library to 20 February 2024, and performed a systematic review and network meta-analysis.
Denosumab usage in atypical cemento-osseous dysplasia involving the entire mandible: a case report.
BMC Oral Health
January 2025
Mackay Memorial Hospital, Taipei, Taiwan.
Background: Cemento-osseous dysplasia (COD) is the most common apical radiopaque lesion that develops in the tooth-bearing area. However, large, destructive lesions are rare. Herein, we report a case in which COD extended to bilateral condyles, affecting the entire mandible, and was managed with denosumab rather than surgical resection.
View Article and Find Full Text PDFUnanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.
BMC Med Res Methodol
January 2025
Clifton Insight, Bristol, UK.
Background: Population-adjusted indirect comparison using parametric Simulated Treatment Comparison (STC) has had limited application to survival outcomes in unanchored settings. Matching-Adjusted Indirect Comparison (MAIC) is commonly used but does not account for violation of proportional hazards or enable extrapolations of survival. We developed and applied a novel methodology for STC in unanchored settings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!